Comparison of breast cancer in Indonesia and Malaysia--a clinico-pathological study between Dharmais Cancer Centre Jakarta and University Malaya Medical Centre, Kuala Lumpur.

INTRODUCTION The age standardised incidence rate (ASR) of breast cancer in Malaysia which is a high middle- income country is similar to Indonesia, a low middle-income country. (Globocan 2008) It is however unknown whether the presentation of breast cancer differs between these two countries. OBJECTIVE We compared the stage, age at presentation, and pathological characteristics of breast cancer between two tertiary hospitals in Indonesia and Malaysia; Dharmais Cancer Centre (DCC), which is the national cancer referral centre in Indonesia, and University Malaya Medical Centre (UMMC), which is an academic hospital with established breast oncology services in Kuala Lumpur. One thousand, one hundred and fourteen consecutive women (477 in UMMC: 637 in DCC) who were newly diagnosed with breast cancer between January and December, 2010 were included. Patient's age, TNM stage at presentation, and pathological characteristics were compared. Estrogen receptor (ER) and progesterone receptor (PR) were considered positive if 10% or greater of invasive cell nuclei were stained while HER2 was considered positive with an immunohistochemistry staining intensity of 3+ . Logistic regression analyses were performed to identify differences. RESULTS Median age at diagnosis was 52 years in UMMC and 47 years in DCC, whereby patients in DCC were more likely to be very young at diagnosis (aged < 35 years) compared to their counterparts in UMMC (Odds ratio (OR): 2.09; 95%CI: 1.32-3.31). Approximately one third of patients in UMMC presented with TNM stage III or IV, compared to 63% in DCC. Patients in DCC were three times more likely to present with metastatic breast cancer compared to patients in UMMC (OR: 3.01; 95% CI: 2.02-4.48). The percentage of low grade tumours in DCC was higher than in UMMC (28% vs 11% respectively), and the difference persisted even after multivariate adjustment. Although the frequency of ER and PR positivity appeared to be higher in UMMC (65% and 55% respectively) compared to DCC (48% and 40% respectively), these differences were not statistically significant following adjustment for age, stage, HER2 status and grade. The frequency of HER2 positivity was 45% in DCC compared to 26% in UMMC, and remained significantly higher even after multivariate adjustment (multivariate OR:1.76; 95%CI:1.25-2.47, in DCC compared to UMMC). The proportion of triple negative breast cancer was however similar in the two centres (19% in UMMC vs 21% in DCC). CONCLUSION Indonesian women with breast cancer seem to present at a younger age and at later stages compared to Malaysian women. Their tumors were more likely to be of low grade and HER2 positive, even after adjustment for other factors, while hormone receptor positivity proved similar in the two groups. The higher HER2 positivity rate in Indonesian patients warrants further study.

[1]  C. Yip,et al.  The Prevalence and Assessment of ErbB2-Positive Breast Cancer in Asia , 2010, Cancer.

[2]  M. J. van de Vijver,et al.  The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  C. Yip,et al.  Breast cancer management in middle-resource countries (MRCs): consensus statement from the Breast Health Global Initiative. , 2011, Breast.

[4]  E. Azavedo,et al.  Guidelines for International Breast Health and Cancer Control – Implementation Supplement to Cancer Guideline Implementation for Breast Healthcare in Low-and Middle-Income Countries Breast Healthcare Program Resource Allocation , 2008 .

[5]  C. Yip Breast cancer in Asia. , 2009, Methods in molecular biology.

[6]  K. Rampal,et al.  Diagnosis delay of breast cancer and its associated factors in Malaysian women , 2011, BMC Cancer.

[7]  H. Verkooijen,et al.  Breast cancer in a multi-ethnic Asian setting: results from the Singapore-Malaysia hospital-based breast cancer registry. , 2011, Breast.

[8]  P. Porter,et al.  "Westernizing" women's risks? Breast cancer in lower-income countries. , 2008, The New England journal of medicine.

[9]  S. Duffy,et al.  Breast cancer in Singapore: trends in incidence 1968-1992. , 1996, International journal of epidemiology.

[10]  S. Teo,et al.  Clinical characteristics of triple-negative breast cancer: experience in an Asian developing country. , 2009, Asian Pacific journal of cancer prevention : APJCP.

[11]  H. Bloom,et al.  Histological Grading and Prognosis in Breast Cancer , 1957, British Journal of Cancer.

[12]  C. Yip,et al.  Recognising symptoms of breast cancer as a reason for delayed presentation in Asian women--the psycho-socio-cultural model for breast symptom appraisal: opportunities for intervention. , 2011, Asian Pacific journal of cancer prevention : APJCP.

[13]  C. Yip,et al.  Survival analysis of Malaysian women with breast cancer: results from the University of Malaya Medical Centre. , 2008, Asian Pacific journal of cancer prevention : APJCP.

[14]  M. Kandiah,et al.  Barriers for breast cancer screening among Asian women: a mini literature review. , 2006, Asian Pacific journal of cancer prevention : APJCP.

[15]  T. Putti,et al.  Clinical Observations from a Breast Cancer Registry in Asian Women , 2007, World Journal of Surgery.

[16]  C. Yip,et al.  Factors affecting estrogen receptor status in a multiracial Asian country: an analysis of 3557 cases. , 2011, Breast.

[17]  Marilys Corbex,et al.  Breast cancer management in low resource countries (LRCs): consensus statement from the Breast Health Global Initiative. , 2011, Breast.

[18]  T. Aryandono,et al.  Survival from operable breast cancer: prognostic factors in Yogyakarta, Indonesia. , 2006, Asian Pacific journal of cancer prevention : APJCP.

[19]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[20]  Z. Shao,et al.  Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients , 2009, Breast Cancer Research and Treatment.